Monoclonal antibodies have been recognised for their significant potential for the treatment of multiple myeloma. At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Christof Scheid, MD, PhD, from the University of Cologne, Cologne, Germany, reviews the clinical development of elotuzumab, which targets CS1, and daratumumab, which targets CD38.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates